Eurofins strengthens its leading analytical testing footprint in Brazil with the acquisition of ASL Análises Ambientais
Tuesday, December 27, 2016
Eurofins Scientific (EUFI.PA), the global leader in food and environment testing, announces that it has acquired ASL Análises Ambientais (“ASL”), one of the leading environment testing service providers in Brazil.
As one of the largest environment testing service providers in the domestic market, ASL serves consulting and industrial companies across Brazil. The company employs about 150 staff and expects to generate revenues in excess of BRL 25m in 2016, with EBITDA margin already at Group objective.
As one of the first signatories of the United Nations Framework Convention on Climate Change (UNFCCC), Brazil has one of the broadest environmental legislations in the world, although enforcement has been sometimes less strong outside of São Paulo. Adoption of regulations by other states in the country should drive further growth in the market. The acquisition of ASL reinforces Eurofins’ leading domestic footprint to leverage its expertise in helping companies comply with existing, as well as future regulations.
Comment from Dr. Gilles Martin, Eurofins CEO: “ASL, together with Anatech, which we acquired in 2014, expands Eurofins’ footprint to become the largest environment testing service provider in Brazil. This transaction reinforces our local footprint and complements our leading position in the domestic food testing market. In return, ASL will have access to the Group’s entire portfolio of competencies, logistics and clients, which should allow it to further expand market share.”
For more information, please visit www.eurofins.com or contact:
Edison de Fraia
Managing Director, Eurofins Brazil
Phone: +55 19 2107 5500
Phone: + 32 2 766 1620
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics and discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the significant emerging players in specialty clinical diagnostic testing in Europe and the USA.
With 25,000 staff in more than 250 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 validated analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.